PeptideScanner

Liraglutide official document review · version 1

This page preserves this version's findings, scope and source pins. Open the current profile →

Inside the official reviews

Reviewed 2026-09-19 · Preserved version 1

The initial glycemic trials and later outcomes trial answer different questions

EMA’s 2009 assessment primarily evaluated glucose control with specific background therapies and comparators. The later LEADER assessment directly evaluated cardiovascular events in a high-risk type 2 diabetes population. EMA PDF pp. 45 ↗EMA PDF pp. 78 ↗

More findings, study links and document coverage

LEADER measured clinical cardiovascular events

The 9,340-participant randomized trial added liraglutide or placebo to standard care. Over median observation of 3.84 years, first major cardiovascular events occurred in 13.0% versus 14.9%; the hazard ratio was 0.87 (95% CI 0.78–0.97). EMA PDF pp. 78 ↗

Do not generalize the high-risk population to everyone

EMA considered the principal endpoint reliable but cautioned about exploratory findings. Results in people with risk factors alone were less consistent; the study did not establish an unrestricted first-line treatment claim for newly diagnosed diabetes. EMA PDF pp. 84, 85, 87 ↗

A composite kidney result is not every kidney outcome

The exploratory nephropathy result was mainly driven by new macroalbuminuria. No differences were found for renal replacement therapy or doubling of creatinine in that analysis; these components should not be presented as equivalent findings. EMA PDF pp. 79 ↗

Read the separate U.S. label account → Label version and indication scope are preserved there; these agency reviews describe their own dated evidence.

Matched study identities

Protocol identifiers were matched to ClinicalTrials.gov records. This does not count extensions as new independent trials.

Document coverage

Selected sections read in 2 of 35 inventoried documents; 33 not yet reviewed. Reading selected sections does not establish complete appraisal of a document.

Selected English EMA PDFs from the retained September 15, 2026 title-matched document feed, plus independently retrieved FDA approval-package documents where listed. Candidate entries are not verified product/application matches. This is a bounded inventory, not a complete FDA, national or worldwide source search. EMA inventory source ↗

Inspect documents, application identities and source pins

Page references use one-based PDF file pages, which can differ from printed page numbers. Candidate feed associations are not verified application identities.

Remaining work

  • Appraise Saxenda weight-management and pediatric documents separately from the Victoza diabetes program.
  • Complete the remaining variation, safety and study-level readings in the candidate inventory.

Open versioned document coverage and study pins →

Public beta · Selective source coverageNot medical advice · No dosing or purchasing guidance